vs
BioNexus Gene Lab Corp（BGLC）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是BioNexus Gene Lab Corp的1815.7倍（$878.4M vs $483.8K）。EXACT SCIENCES CORP净利率更高（-9.8% vs -214.2%，领先204.4%）。EXACT SCIENCES CORP同比增速更快（23.1% vs -80.8%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $960.1K）。过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -54.9%）
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
BGLC vs EXAS — 直观对比
营收规模更大
EXAS
是对方的1815.7倍
$483.8K
营收增速更快
EXAS
高出104.0%
-80.8%
净利率更高
EXAS
高出204.4%
-214.2%
自由现金流更多
EXAS
多$119.5M
$960.1K
两年增速更快
EXAS
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $483.8K | $878.4M |
| 净利润 | $-1.0M | $-86.0M |
| 毛利率 | -0.8% | 70.1% |
| 营业利润率 | -213.5% | -9.4% |
| 净利率 | -214.2% | -9.8% |
| 营收同比 | -80.8% | 23.1% |
| 净利润同比 | -197.5% | 90.1% |
| 每股收益（稀释后） | — | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGLCEXAS
| Q4 25 | $483.8K | $878.4M | ||
| Q3 25 | $2.5M | $850.7M | ||
| Q2 25 | $2.3M | $811.1M | ||
| Q1 25 | $2.1M | $706.8M | ||
| Q4 24 | $2.5M | $713.4M | ||
| Q3 24 | $2.6M | $708.7M | ||
| Q2 24 | $2.0M | $699.3M | ||
| Q1 24 | $2.4M | $637.5M |
净利润BGLCEXAS
| Q4 25 | $-1.0M | $-86.0M | ||
| Q3 25 | $-709.0K | $-19.6M | ||
| Q2 25 | $-616.2K | $-1.2M | ||
| Q1 25 | $-623.3K | $-101.2M | ||
| Q4 24 | $-348.3K | $-864.6M | ||
| Q3 24 | $-1.3M | $-38.2M | ||
| Q2 24 | $199.1K | $-15.8M | ||
| Q1 24 | $-103.8K | $-110.2M |
毛利率BGLCEXAS
| Q4 25 | -0.8% | 70.1% | ||
| Q3 25 | 14.8% | 68.6% | ||
| Q2 25 | 16.3% | 69.3% | ||
| Q1 25 | 16.1% | 70.8% | ||
| Q4 24 | 12.3% | 69.0% | ||
| Q3 24 | 12.4% | 69.4% | ||
| Q2 24 | 14.6% | 69.8% | ||
| Q1 24 | 15.3% | 70.0% |
营业利润率BGLCEXAS
| Q4 25 | -213.5% | -9.4% | ||
| Q3 25 | -27.6% | -3.0% | ||
| Q2 25 | -27.0% | -0.3% | ||
| Q1 25 | -28.9% | -13.6% | ||
| Q4 24 | -16.5% | -122.8% | ||
| Q3 24 | -50.9% | -5.6% | ||
| Q2 24 | 13.1% | -3.8% | ||
| Q1 24 | -3.3% | -16.7% |
净利率BGLCEXAS
| Q4 25 | -214.2% | -9.8% | ||
| Q3 25 | -27.9% | -2.3% | ||
| Q2 25 | -27.3% | -0.1% | ||
| Q1 25 | -29.2% | -14.3% | ||
| Q4 24 | -13.8% | -121.2% | ||
| Q3 24 | -51.1% | -5.4% | ||
| Q2 24 | 10.1% | -2.3% | ||
| Q1 24 | -4.4% | -17.3% |
每股收益（稀释后）BGLCEXAS
| Q4 25 | — | $-0.45 | ||
| Q3 25 | $-0.40 | $-0.10 | ||
| Q2 25 | $-0.34 | $-0.01 | ||
| Q1 25 | $-0.04 | $-0.54 | ||
| Q4 24 | $0.55 | $-4.69 | ||
| Q3 24 | $-0.75 | $-0.21 | ||
| Q2 24 | $0.11 | $-0.09 | ||
| Q1 24 | $-0.01 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $964.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6M | $2.4B |
| 总资产 | $9.3M | $5.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGLCEXAS
| Q4 25 | $2.5M | $964.7M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $858.4M | ||
| Q1 25 | — | $786.2M | ||
| Q4 24 | $2.9M | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $946.8M | ||
| Q1 24 | — | $652.1M |
股东权益BGLCEXAS
| Q4 25 | $8.6M | $2.4B | ||
| Q3 25 | $6.8M | $2.5B | ||
| Q2 25 | $7.5M | $2.5B | ||
| Q1 25 | $7.8M | $2.4B | ||
| Q4 24 | $8.3M | $2.4B | ||
| Q3 24 | $9.4M | $3.2B | ||
| Q2 24 | $9.5M | $3.2B | ||
| Q1 24 | $9.3M | $3.1B |
总资产BGLCEXAS
| Q4 25 | $9.3M | $5.9B | ||
| Q3 25 | $7.6M | $5.9B | ||
| Q2 25 | $9.4M | $5.8B | ||
| Q1 25 | $9.5M | $5.7B | ||
| Q4 24 | $10.4M | $5.9B | ||
| Q3 24 | $11.0M | $6.7B | ||
| Q2 24 | $11.1M | $6.7B | ||
| Q1 24 | $11.2M | $6.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $961.1K | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $960.1K | $120.4M |
| 自由现金流率自由现金流/营收 | 198.5% | 13.7% |
| 资本支出强度资本支出/营收 | 0.2% | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9M | $356.8M |
8季度趋势，按日历期对齐
经营现金流BGLCEXAS
| Q4 25 | $961.1K | $151.7M | ||
| Q3 25 | $-1.2M | $219.9M | ||
| Q2 25 | $-737.9K | $89.0M | ||
| Q1 25 | $-824.1K | $30.8M | ||
| Q4 24 | $219.2K | $47.1M | ||
| Q3 24 | $-1.6M | $138.7M | ||
| Q2 24 | $-672.3K | $107.1M | ||
| Q1 24 | $-37.2K | $-82.3M |
自由现金流BGLCEXAS
| Q4 25 | $960.1K | $120.4M | ||
| Q3 25 | $-1.2M | $190.0M | ||
| Q2 25 | $-759.4K | $46.7M | ||
| Q1 25 | $-833.1K | $-365.0K | ||
| Q4 24 | $215.2K | $10.7M | ||
| Q3 24 | $-1.8M | $112.6M | ||
| Q2 24 | $-674.1K | $71.2M | ||
| Q1 24 | $-59.1K | $-120.0M |
自由现金流率BGLCEXAS
| Q4 25 | 198.5% | 13.7% | ||
| Q3 25 | -48.9% | 22.3% | ||
| Q2 25 | -33.6% | 5.8% | ||
| Q1 25 | -39.0% | -0.1% | ||
| Q4 24 | 8.5% | 1.5% | ||
| Q3 24 | -68.5% | 15.9% | ||
| Q2 24 | -34.1% | 10.2% | ||
| Q1 24 | -2.5% | -18.8% |
资本支出强度BGLCEXAS
| Q4 25 | 0.2% | 3.6% | ||
| Q3 25 | 0.2% | 3.5% | ||
| Q2 25 | 0.9% | 5.2% | ||
| Q1 25 | 0.4% | 4.4% | ||
| Q4 24 | 0.2% | 5.1% | ||
| Q3 24 | 7.6% | 3.7% | ||
| Q2 24 | 0.1% | 5.1% | ||
| Q1 24 | 0.9% | 5.9% |
现金转化率BGLCEXAS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.38× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGLC
暂无分部数据
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
